CAL
TNXP icon

Capital Advisors Ltd’s Tonix Pharmaceuticals TNXP Stock Holding History

Capital Advisors Ltd’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8
Closed – – 1577
2024
Q3 		$0 Buy
+8
New +$322 ﹤0.01% 1606
2024
Q2 		– Hold
0
– – – 1633
2024
Q1 		– Hold
0
– – – 1545

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.15B AUM 25.5% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Capital Advisors Ltd's TNXP Position: Q4 2024 in Review

Capital Advisors Ltd sold out of Tonix Pharmaceuticals (TNXP) in Q4 2024, closing a stake of 8 shares.

Capital Advisors Ltd first reported a position in TNXP in Q3 2024 and held it in 1 quarter. The position peaked at $0 in Q3 2024. 32 funds tracked by Wall St. Rank hold TNXP as of Q4 2024.

  • Capital Advisors Ltd reported no remaining Tonix Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Advisors Ltd sold 8 Tonix Pharmaceuticals shares in Q4 2024.
  • Capital Advisors Ltd first reported a position in Tonix Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Advisors Ltd's Tonix Pharmaceuticals position peaked at $0 in Q3 2024.
  • 32 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q4 2024.

Based on Capital Advisors Ltd's 13F filing for Q4 2024, filed 4 Feb 2025.